Next Article in Journal / Special Issue
New Conotoxin SO-3 Targeting N-type Voltage-Sensitive Calcium Channels
Previous Article in Journal / Special Issue
Marine Toxins That Target Voltage-gated Sodium Channels
Mar. Drugs 2006, 4(3), 193-214; doi:10.3390/md403193
Review

ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential

 and *
Institute for Molecular Bioscience, The University of Queensland, St Lucia, 4072, QLD, Australia
* Author to whom correspondence should be addressed.
Received: 16 February 2006 / Accepted: 28 February 2006 / Published: 6 April 2006
(This article belongs to the Special Issue Marine Drugs and Ion Channels)
View Full-Text   |   Download PDF [419 KB, uploaded 24 February 2015]   |  

Abstract

Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain.
Keywords: ω-conotoxin; Structure-Activity relationship; pain ω-conotoxin; Structure-Activity relationship; pain
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Schroeder, C.I.; Lewis, R.J. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential. Mar. Drugs 2006, 4, 193-214.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert